Victory Capital Management Inc. Trims Position in Hims & Hers Health, Inc. $HIMS

Victory Capital Management Inc. lowered its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 8.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 252,751 shares of the company’s stock after selling 23,364 shares during the quarter. Victory Capital Management Inc. owned about 0.11% of Hims & Hers Health worth $14,336,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Virtus Advisers LLC acquired a new position in Hims & Hers Health in the 2nd quarter valued at about $26,000. Quent Capital LLC purchased a new stake in shares of Hims & Hers Health during the 3rd quarter valued at approximately $28,000. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health during the 1st quarter valued at approximately $30,000. Hilltop National Bank acquired a new position in Hims & Hers Health in the third quarter valued at approximately $35,000. Finally, Skandinaviska Enskilda Banken AB publ lifted its holdings in Hims & Hers Health by 408.2% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company’s stock valued at $37,000 after acquiring an additional 600 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Patrick Harrison Carroll sold 10,021 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $367,870.91. Following the sale, the insider directly owned 169,940 shares in the company, valued at approximately $6,238,497.40. This trade represents a 5.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Oluyemi Okupe sold 23,090 shares of the business’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $35.72, for a total transaction of $824,774.80. Following the transaction, the chief financial officer owned 94,333 shares of the company’s stock, valued at approximately $3,369,574.76. The trade was a 19.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 80,463 shares of company stock valued at $2,846,696 over the last ninety days. 17.71% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Barclays cut their target price on Hims & Hers Health from $48.00 to $25.00 and set an “overweight” rating for the company in a research note on Tuesday, February 24th. TD Cowen lowered their price target on Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating for the company in a report on Tuesday, February 24th. BTIG Research downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating in a research report on Tuesday, February 24th. Morgan Stanley decreased their target price on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 24th. Finally, Needham & Company LLC raised shares of Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a research note on Monday. Three investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $30.46.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $23.47 on Wednesday. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. The company has a market cap of $5.35 billion, a price-to-earnings ratio of 46.01, a price-to-earnings-growth ratio of 4.24 and a beta of 2.55. The stock’s 50-day moving average is $24.31 and its two-hundred day moving average is $37.75. Hims & Hers Health, Inc. has a 1-year low of $13.74 and a 1-year high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The business had revenue of $617.82 million during the quarter, compared to analysts’ expectations of $619.48 million. During the same quarter last year, the business posted $0.11 EPS. The business’s quarterly revenue was up 28.4% compared to the same quarter last year. Analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health declared that its board has approved a share repurchase plan on Monday, November 17th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 3% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its stock is undervalued.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Strategic partnership with Novo Nordisk ends litigation risk and adds GLP‑1 revenue opportunity — this is the core catalyst lifting the stock by re-opening access to Ozempic/Wegovy on HIMS’ platform. Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic
• Positive Sentiment: Needham & Company upgraded HIMS to Buy and set a $30 price target, citing the Novo deal as a major de‑risking and upside to the revenue outlook. Hims & Hers Health (NYSE:HIMS) Raised to “Buy” at Needham & Company LLC
• Positive Sentiment: Large bullish options flow: investors bought roughly 322,282 call options (≈+128% vs. typical volume), signaling short‑term speculative conviction or hedging ahead of potential upside. Hims & Hers Health Target of Unusually Large Options Trading (NYSE:HIMS)
• Positive Sentiment: Multiple brokers raised ratings/targets (Citigroup, Deutsche Bank, Bank of America among others), shifting sentiment toward the stock and supporting near‑term buying interest. Hims and Hers Expands Consumer-Focused Digital Health Platform
• Neutral Sentiment: Company named Kathryn Beiser as Chief Communications Officer — improves investor / brand communications as HIMS scales, but is not an immediate revenue driver. Hims & Hers Names Kathryn Beiser as Chief Communications Officer
• Neutral Sentiment: Consensus remains mixed: broker consensus still averages a “Hold” and analysts are split on sustainability of the rally — expect divergent views to drive volatility. Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Rating of “Hold” from Brokerages
• Negative Sentiment: Regulatory / legal scrutiny and a newly announced investigation of officers/directors remain risks — while the Novo settlement reduced one major legal overhang, other inquiries and class/derivative claims could emerge. Hims & Hers Health Investigation Initiated
• Negative Sentiment: Warnings about unsustainable gains and short‑squeeze dynamics — high short interest and heavy speculative flows can amplify both upside and rapid drawdowns; some analysts caution today’s move may not be durable. Hims & Hers stock: why today’s gains are unlikely to be sustainable

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.